Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ghina Alameh, Agnès Emptoz-Bonneton, Marc Rolland de Ravel, Eva L. Matera, Elisabeth Mappus, Patrick Balaguer, Luc Rocheblave, Thierry Lomberget, Charles Dumontet, Marc Le Borgne, Michel Pugeat, Catherine Grenot & Claude Y. Cuilleron. (2019) In vitro modulation of multidrug resistance by pregnane steroids and in vivo inhibition of tumour development by 7α-OBz-11α(R)-OTHP-5β-pregnanedione in K562/R7 and H295R cell xenografts. Journal of Enzyme Inhibition and Medicinal Chemistry 34:1, pages 684-691.
Read now
Read now
Francis Loor. (1999) Valspodar: current status and perspectives. Expert Opinion on Investigational Drugs 8:6, pages 807-835.
Read now
Read now
Articles from other publishers (10)
Alessia Carocci, Alessia Catalano, Francesco Turi, Angelo Lovece, Maria M. Cavalluzzi, Claudio Bruno, Nicola A. Colabufo, Marialessandra Contino, Maria G. Perrone, Carlo Franchini & Giovanni Lentini. (2016) Stereoselective Modulation of P-Glycoprotein by Chiral Small Molecules. ChemMedChem 11:1, pages 93-101.
Crossref
Crossref
Youssef Ramli, Ahmed Moussaif, Khalid Karrouchi & El Mokhtar Essassi. (2014) Pharmacological Profile of Quinoxalinone. Journal of Chemistry 2014, pages 1-21.
Crossref
Crossref
Iveta Bottova, Ursula Sauder, Vesna Olivieri, Adrian B. Hehl & Sabrina Sonda. (2010) The P-glycoprotein Inhibitor GF120918 Modulates Ca2+-Dependent Processes and Lipid Metabolism in Toxoplasma Gondii. PLoS ONE 5:4, pages e10062.
Crossref
Crossref
Li-rui Sun, Xun Li, Yan-na Cheng, Hong-yu Yuan, Ming-hui Chen, Wei Tang, Stephen Geoffrey Ward & Xian-jun Qu. (2009) Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells. Biomedicine & Pharmacotherapy 63:3, pages 202-208.
Crossref
Crossref
Gong-Wen Liang, Wan-Liang Lu, Jin-Wei Wu, Ji-Hui Zhao, Hai-Yan Hong, Chuan Long, Ting Li, Yu-Teng Zhang, Hua Zhang, Jian-Cheng Wang, Xuan Zhang & Qiang Zhang. (2008) Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundamental & Clinical Pharmacology 22:4, pages 429-437.
Crossref
Crossref
Nicola Antonio Colabufo, Francesco Berardi, Mariangela Cantore, Maria Grazia Perrone, Marialessandra Contino, Carmela Inglese, Mauro Niso, Roberto Perrone, Amalia Azzariti, Grazia Maria Simone, Letizia Porcelli & Angelo Paradiso. (2008) Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorganic & Medicinal Chemistry 16:1, pages 362-373.
Crossref
Crossref
Leena Gandhi, Matthew W. Harding, Marcus Neubauer, Corey J. Langer, Melvin Moore, Helen J. Ross, Bruce E. Johnson & Thomas J. Lynch. (2007) A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109:5, pages 924-932.
Crossref
Crossref
X. Li, W. L. Lu, G. W. Liang, G. R. Ruan, H. Y. Hong, C. Long, Y. T. Zhang, Y. Liu, J. C. Wang, X. Zhang & Q. Zhang. (2006) Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. European Journal of Clinical Investigation 36:6, pages 409-418.
Crossref
Crossref
Xing Li, Guo-Rui Ruan, Wan-Liang Lu, Hai-Yan Hong, Gong-Wen Liang, Yu-Teng Zhang, Yang Liu, Chuan Long, Xi Ma, Lan Yuan, Jian-Cheng Wang, Xuan Zhang & Qiang Zhang. (2006) A novel stealth liposomal topotecan with amlodipine: Apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. Journal of Controlled Release 112:2, pages 186-198.
Crossref
Crossref
Yuliya A. Dahlem, Gerald Wolf, Detlef Siemen & Thomas F.W. Horn. (2006) Combined modulation of the mitochondrial ATP-dependent potassium channel and the permeability transition pore causes prolongation of the biphasic calcium dynamics. Cell Calcium 39:5, pages 387-400.
Crossref
Crossref